Everything You Should Know About Quipt Home Medical (QIPT) Rating Increase to Buy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 25 2025
0mins
Source: NASDAQ.COM
Quipt Home Medical Corp. Upgrade: Quipt Home Medical Corp. has received a Zacks Rank #2 (Buy) due to a significant increase in earnings estimates, indicating a positive outlook for the company's stock price.
Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, shows that Quipt is in the top 20% of covered stocks, suggesting potential for market-beating returns in the near term.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like QIPT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on QIPT
Wall Street analysts forecast QIPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QIPT is 3.77 USD with a low forecast of 3.65 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
1 Hold
1 Sell
Hold
Current: 3.580
Low
3.65
Averages
3.77
High
4.00
Current: 3.580
Low
3.65
Averages
3.77
High
4.00
About QIPT
Quipt Home Medical Corp. provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. The Company's expertise spans across a full spectrum of respiratory care, providing an end-to-end solution for medical providers and patients. This includes technology enabled equipment offerings and specialized care for patients with cardio and pulmonary diseases, sleep disorders, mobility challenges, and other chronic disease management. The Company's healthcare products and services include sleep apnea and pap treatment, home medical equipment, home ventilation and custom mobility solutions. It has a 60% ownership interest in Hart Medical Equipment, which maintains strategic relationships with integrated health systems and freestanding community-based hospitals, embedding the business into the hospital discharge processes of more than 19 hospitals and affiliated care facilities across its network.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ademi Firm Investigates Quipt's $260M Transaction with Kingswood for Fiduciary Breaches
- Investigation Launched: The Ademi Firm is investigating Quipt's transaction with Kingswood for potential breaches of fiduciary duty and legal violations, focusing on whether the Quipt board is fulfilling its responsibilities to all shareholders.
- Transaction Valuation: In this deal, Quipt shareholders will receive $3.65 per share, valuing the company at approximately $260 million, including its existing outstanding debt, indicating a significant impact on the company's financial standing.
- Competition Restrictions: The transaction agreement imposes significant penalties on Quipt for accepting competing bids, which could harm shareholder interests and lead to legal disputes regarding the board's conduct.
- Insider Benefits: Quipt insiders will receive substantial benefits as part of the change of control arrangements, raising concerns about the board's actions and potentially affecting the transparency of corporate governance and shareholder trust.
Continue Reading
Quipt Home Medical to Sell for $3.65 per Share to Kingswood and Forager
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Quipt Home Medical Corp.'s sale for $3.65 per share, which may violate federal securities laws and impact shareholder rights.
- Merger Transaction Impact: The merger between Fifth Third Bancorp and Comerica Incorporated will result in Fifth Third shareholders owning approximately 73% of the combined entity, potentially altering shareholder control and corporate governance structures.
- Potential Payment Rights: Generation Bio Co. is being sold for $4.2913 per share, along with a non-transferable contingent value right, which could provide shareholders with additional potential payments, enhancing investment appeal.
- Legal Rights Protection: Halper Sadeh LLC offers free consultations to help shareholders understand their legal rights and options, aiming to secure increased consideration and additional disclosures for affected investors.
Continue Reading